UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
IMMUNOCELLULAR THERAPEUTICS, LTD.
(Exact name of registrant as specified in its charter)
Delaware  
(State of incorporation or organization)
 
93-1301885  
(I.R.S. Employer Identification No.)
 
23622 Calabasas Road, Suite 300
Calabasas, California  
(Address of principal executive offices)
 
 
91302  
(Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:
 
 
 
Title of each class
to be so registered
 
 
Name of each exchange on which
each class is to be registered
 
Warrants to purchase Common Stock, $0.0001 par value per share
 
 
The NYSE MKT
 
 
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ý
 
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨
 
Securities Act registration statement file number to which this form relates: 333-211763
Securities to be registered pursuant to Section 12(g) of the Act: None
 
 
 








INFORMATION REQUIRED IN REGISTRATION STATEMENT

Item 1. Description of Registrant’s Securities to be Registered.
A description of the warrants to purchase common stock, par value $0.0001 per share, of ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Registrant”), to be registered hereunder is contained in the section entitled “Description of Securities we are Offering” in the prospectus included in the Registrant’s Registration Statement on Form S-1 (File No. 333-211763), initially filed with the Securities and Exchange Commission on June 1, 2016, as amended from time to time (the “Registration Statement”), and is incorporated herein by reference. In addition, a description of the warrants will be included in a prospectus to be subsequently filed by the Registrant pursuant to Rule 424(b) of the Securities Act of 1933, as amended, relating to the Registration Statement, and such prospectus will be deemed incorporated herein by reference.

Item 2. Exhibits.
The following exhibits are incorporated by reference from the Registrant’s filings with the Securities and Exchange Commission:
 
 
 
 
 
 
 
Exhibit
Number
 
Description
 
Registrant’s
Form
Date Filed with
The SEC
Exhibit
Number
 
 
 
 
 
 
 
3.1
 
Amended and Restated Certificate of Incorporation.
 
8-K
9/24/2013
3.1
 
 
 
 
 
 
 
3.2
 
Certificate of Amendment to Amended and Restated Certificate of Incorporation.
 
8-K
11/19/2015
3.1
 
 
 
 
 
 
 
3.3
 
Amended and Restated Bylaws.
 
S-8
1/11/2011
3.1
 
 
 
 
 
 
 
4.1
 
Form of Common Stock Certificate of the Registrant.
 
SB-2
2/12/2007
4.1
 
 
 
 
 
 
 
4.2
 
Form of Common Stock Warrant Agreement and Warrant Certificate
 
S-1/A
8/4/2016
4.8
 
 


 



SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
IMMUNOCELLULAR THERAPEUTICS, LTD.
 
 
 
 
Date: August 3, 2016
 
By:
/s/ David Fractor
 
 
 
David Fractor
 
 
 
Vice President, Finance and Principal Accounting Officer
 

EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more EOM Pharmaceutical (PK) Charts.
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more EOM Pharmaceutical (PK) Charts.